Logo image of NBSE

NEUBASE THERAPEUTICS INC (NBSE) Stock Fundamental Analysis

NASDAQ:NBSE - Nasdaq - US64132K2015 - Common Stock - Currency: USD

0.378  -0.01 (-3.2%)

After market: 0.42 +0.04 (+11.11%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to NBSE. NBSE was compared to 562 industry peers in the Biotechnology industry. The financial health of NBSE is average, but there are quite some concerns on its profitability. NBSE does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year NBSE has reported negative net income.
In the past year NBSE had a positive cash flow from operations.
In the past 5 years NBSE always reported negative net income.
In the past 5 years NBSE always reported negative operating cash flow.
NBSE Yearly Net Income VS EBIT VS OCF VS FCFNBSE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M

1.2 Ratios

NBSE has a Return On Assets of -73.74%. This is in the lower half of the industry: NBSE underperforms 69.40% of its industry peers.
NBSE has a Return On Equity of -150.22%. This is in the lower half of the industry: NBSE underperforms 65.98% of its industry peers.
Industry RankSector Rank
ROA -73.74%
ROE -150.22%
ROIC N/A
ROA(3y)-64.47%
ROA(5y)-103.16%
ROE(3y)-82.74%
ROE(5y)-126.04%
ROIC(3y)N/A
ROIC(5y)N/A
NBSE Yearly ROA, ROE, ROICNBSE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50 -100 -150 -200 -250

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for NBSE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NBSE Yearly Profit, Operating, Gross MarginsNBSE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022

More info and screens

5

2. Health

2.1 Basic Checks

NBSE has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, NBSE has more shares outstanding
The debt/assets ratio for NBSE has been reduced compared to a year ago.
NBSE Yearly Shares OutstandingNBSE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 500K 1M 1.5M
NBSE Yearly Total Debt VS Total AssetsNBSE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M

2.2 Solvency

Based on the Altman-Z score of -10.48, we must say that NBSE is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of NBSE (-10.48) is worse than 78.97% of its industry peers.
NBSE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z -10.48
ROIC/WACCN/A
WACCN/A
NBSE Yearly LT Debt VS Equity VS FCFNBSE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M

2.3 Liquidity

NBSE has a Current Ratio of 2.87. This indicates that NBSE is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 2.87, NBSE is doing worse than 68.03% of the companies in the same industry.
NBSE has a Quick Ratio of 2.87. This indicates that NBSE is financially healthy and has no problem in meeting its short term obligations.
NBSE's Quick ratio of 2.87 is on the low side compared to the rest of the industry. NBSE is outperformed by 66.50% of its industry peers.
Industry RankSector Rank
Current Ratio 2.87
Quick Ratio 2.87
NBSE Yearly Current Assets VS Current LiabilitesNBSE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M

More info and screens

1

3. Growth

3.1 Past

NBSE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 55.05%, which is quite impressive.
EPS 1Y (TTM)55.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%86.25%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

NBSE is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.88% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-25.75%
EPS Next 2Y-26.21%
EPS Next 3Y21.21%
EPS Next 5Y14.88%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NBSE Yearly EPS VS EstimatesNBSE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2019 2020 2021 2022 2023 2024 2025 2026 2027 -5 -10 -15 -20 -25

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

NBSE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year NBSE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NBSE Price Earnings VS Forward Price EarningsNBSE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Compared to the rest of the industry, the Price/Free Cash Flow ratio of NBSE indicates a rather cheap valuation: NBSE is cheaper than 100.00% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 0.1
EV/EBITDA N/A
NBSE Per share dataNBSE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4 -6 -8

4.3 Compensation for Growth

NBSE's earnings are expected to grow with 21.21% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-26.21%
EPS Next 3Y21.21%

More info and screens

0

5. Dividend

5.1 Amount

NBSE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NEUBASE THERAPEUTICS INC

NASDAQ:NBSE (5/10/2024, 8:08:45 PM)

After market: 0.42 +0.04 (+11.11%)

0.378

-0.01 (-3.2%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13 2024-05-13
Earnings (Next)08-12 2024-08-12
Inst Owners3.64%
Inst Owner Change0%
Ins Owners12.28%
Ins Owner Change0%
Market Cap1.42M
Analysts43.33
Price Target142.8 (37677.78%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-1.15%
Min EPS beat(2)-2.3%
Max EPS beat(2)0%
EPS beat(4)2
Avg EPS beat(4)10.77%
Min EPS beat(4)-2.3%
Max EPS beat(4)30.42%
EPS beat(8)4
Avg EPS beat(8)4.45%
EPS beat(12)6
Avg EPS beat(12)1.88%
EPS beat(16)8
Avg EPS beat(16)-38.03%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF 0.1
P/OCF 0.1
P/B 0.16
P/tB 0.16
EV/EBITDA N/A
EPS(TTM)-7.3
EYN/A
EPS(NY)-9.18
Fwd EYN/A
FCF(TTM)3.9
FCFY1032.8%
OCF(TTM)3.79
OCFY1003.88%
SpS0
BVpS2.44
TBVpS2.44
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -73.74%
ROE -150.22%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-64.47%
ROA(5y)-103.16%
ROE(3y)-82.74%
ROE(5y)-126.04%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA N/A
Cap/Depr -683.33%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.87
Quick Ratio 2.87
Altman-Z -10.48
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)226.06%
Cap/Depr(5y)214.1%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)55.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%86.25%
EPS Next Y-25.75%
EPS Next 2Y-26.21%
EPS Next 3Y21.21%
EPS Next 5Y14.88%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y59.83%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y213.93%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y219.18%
OCF growth 3YN/A
OCF growth 5YN/A